Abstract
Journal of Cancer Metastasis and Treatment is an open access journal, focusing on basic and clinical studies related to cancer cell, cell biology, oncology, radiation therapy and radiology, obstetrics and gynecology, pediatrics, surgery, hematology, neuro-oncology, etc.
Highlights
Renal cell carcinoma (RCC) accounts for 3% of all cancers worldwide and is the most common solid tumor within the kidney representing approximately 90% of all kidney malignancies[1]
The majority of the lesions is diagnosed as small tumors, with a notable proportion of locally advanced disease and up to 20% of patients presenting with distant metastases at the time of diagnosis[1]
About 20%-40% of non-metastatic patients will eventually develop metastases, for which the standard management consists of immune checkpoint inhibitors (ICI) and/or targeted therapy[2,3]
Summary
Renal cell carcinoma (RCC) accounts for 3% of all cancers worldwide and is the most common solid tumor within the kidney representing approximately 90% of all kidney malignancies[1]. SBRT for primary RCC has proven to be effective and well-tolerated, and might even lead to more favorable local control rates when compared to thermal ablative treatments, certainly in case of stage Ib tumors[12]. Oligometastatic disease, the intermediate state between localized and widespread metastatic disease, typically involves 1-5 metastases In this particular situation, metastasis-directed therapy (MDT) has evolved as a new treatment option in various tumors, with prostate cancer probably being the most studied urological tumor[16]. Frick et al.[4], reported on the use of proton SBRT in a 47-year-old women diagnosed with bilateral Grade 1-2 clear cell RCCs. The patient was inoperable due to multiple comorbidities including stage 2 chronic kidney disease (CKD). Dose to the remaining target kidney, contralateral kidney, liver, spinal cord, and intestine was limited
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
